Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults (VINILO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01884922
Recruitment Status : Unknown
Verified January 2017 by Gustave Roussy, Cancer Campus, Grand Paris.
Recruitment status was:  Recruiting
First Posted : June 24, 2013
Last Update Posted : January 26, 2017
Information provided by (Responsible Party):
Gustave Roussy, Cancer Campus, Grand Paris

Brief Summary:
Multicenter, open label, prospective study including successively a phase I trial and then a phase II trial Phase I : Open label, non-randomized, sequential dose escalation of both drugs, vinblastine and nilotinib.

Condition or disease Intervention/treatment Phase
Refractory Low-grade Gliomas Recurrent Low-grade Gliomas Drug: Nilotinib Drug: Vinblastine Phase 1

Detailed Description:

Low grade gliomas (LGG) are the most frequent brain tumor type in children. They are often chemosensitive. However, more than 50% of these tumors will progress within the first 5 years after the start of the treatment and need a second-line therapy (Laithier, JCO 2003). In most cases, patients are still young and the risk of side effects from radiation therapy will call for another medical treatment. If a tumor does not respond to first-line chemotherapy, the prognosis worsens with 25% of deaths within the first 5 years for optic gliomas (de Haas, Pediatr Blood Cancer 2009). Vinblastine (Velbe®) is an effective drug for low grade gliomas with both antiproliferative and antiangiogenic effects. An update of the Canadian phase II of weekly vinblastine (6 mg/m²/week) reported one complete response (CR), three partial responses (PR) and 9 minor responses (MR) in the first 31 patients (Bouffet, Abstract in Neuro-Oncology 2008). The 1-year progressionfree survival (PFS) rate was 57%. Tolerance of the treatment is fair allowing prolonged maintenance therapy as in Langerhans cell histiocytosis and anaplastic large cell lymphoma (ALCL). These data encourage proceeding with further testing this approach in pediatric low-grade glioma.

Nilotinib is a tyrosine kinase inhibitor (TKI) known to affect c-Kit, DDR1 and the PDGF receptors alpha and beta. PDGF is a growth factor for normal and tumoral astrocytes and oligodendrocytes. In addition, PDGF receptors are expressed on pediatric low-grade glioma vessels (McLaughlin, J Pediatr Hematol Oncol 2003; Peyrl, Pediatr Blood Cancer 2009). Tumor response to this class of TKI has been reported occasionally (Peyrl, Pediatr Blood Cancer 2009; McLaughlin, J Pediatr Hematol Oncol 2003). When used as monotherapy, this class of TKI was well tolerated in children, including those with brain tumors (Wayne, Blood 2008; Baruchel, Eur J Cancer 2009; Geoerger, Eur J Cancer 2009). Taking advantage of their different antiangiogenic mechanisms, their limited and non-overlapping toxicities, vinblastine and nilotinib could play an interesting role in the treatment of pediatric low-grade glioma. Nilotinib via PDGFRA and c-kit interactions may also interfere with the stroma of the tumor which is a key factor for tumor growth as shown in the NF1 mouse model (Daginakatte, Cancer Res 2008; Kim, Neuroscience 2010; Simmons, J Neuropathol Exp Neurol 2011). Both drugs have also immunostimulating effects especially in dendritic cells, that will be explored during treatment in selected patients (Tanaka, Cancer Res 2009; Nishioka Immunotherapy 2011) Previous to the phase II assessing the efficacy of the combination compared to vinblastine as single agent, nilotinib and vinblastine have to be administered by escalating dosages in order to identify the recommended doses of each agent when given in combination. This phase I part of the trial is justified by a possible interaction of the two drugs that are substrates of cytochrome P450 CYP3A4. Initial/starting dose of nilotinib (115 mg/m² BID) will be 50% of the recommended dose when used as monotherapy in adults (800 mg/day: 400 mg BID =230 mg/m2 BID). Initial/starting dose of vinblastine will be 50% of the recommended dose when used as monotherapy or in association with other chemotherapeutic drugs (i.e. 3 mg/m2 once a week). This justifies obtaining pharmacokinetic data on both drugs when used in combination. A phase I trial evaluating nilotinib as single agent in pediatrics in hematological malignancies is ongoing, run by the ITCC and the COG group, exploring the dose-levels 230 mg/m² to 460 mg/m² BID. The results of this phase I trial, expected by 2012, and the data of the current trial will be considered to decide whether a higher dose-level for nilotinib can be opened (350 mg/m² BID).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : May 2013
Estimated Primary Completion Date : May 2017
Estimated Study Completion Date : May 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Dose escalation

Nilotinib (Tasigna®): 115 to 350 mg/m2 twice daily (BID) orally given continuously (115 mg/m2 once daily if de-escalation requested

Vinblastine: 3 to 6 mg/m2 once weekly in a 15-minute infusion, on Days 1, 8, 15 and 22 of each cycle.

Drug: Nilotinib
Tasigna®(nilotinib):: 50 mg, 150 mg and 200 mg capsules. Tasigna® capsules contain lactose monohydrate, crospovidone, poloxamer, colloidal silicon dioxide and magnesium. Orally; the capsules should be swallowed as a whole with water. No food should be consumed for 2 hours before the dose is taken and for at least one hour thereafter. For patients who are unable to swallow capsules, the content of each capsule may be dispersed in one teaspoon of apple sauce or compote or nonfat plain yogurt and should be taken immediately. Not more than one teaspoon of apple sauce / yogourt, and no food other than apple sauce or nonfat plain yogurt must be used.
Other Name: Tasigna®

Drug: Vinblastine

Vinblastine: 3 to 6 mg/m2 once weekly in a 15-minute infusion, on Days 1, 8, 15 and 22 of each cycle.

Each 28-day cycle is repeated on Day 29/Day 1. No intra-patient doseescalation is permitted. Dose allocation will be centrally defined, based on toxicity observed in patients previously evaluated. Every new patient will be treated at the best current recommended dose, i.e. the dose associated with an estimated level of toxicity that is judged acceptable (20% DLT). At least two patients fully observed with no DLT are requested at a given dose level before dose escalation.

Primary Outcome Measures :
  1. Safety Assessment - Dose-Limiting Toxicity (DLT) [ Time Frame: Assessed over the first 28-day cycle ]

    Dose-Limiting Toxicity (DLT), assessed over the first 28-day cycle, defined as

    • Grade > 3 neutropenia (<1 x 109/L) for more than 7 days;
    • Grade > 2 thrombopenia (<75 x 109/L) or thrombocytopenia requiring transfusions for more than 7 days.
    • Grade 3 or grade 4 non-hematological toxicity, excluding grade 3 nausea, vomiting, fever, and hepatic toxicity that is rapidly reversible (i.e. returns to < 2.5 x ULN within 2 weeks after study drug discontinuation), and symptoms that are related to tumor progression.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Months to 20 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Written informed consent signed by the patient, or parents or legal representative and assent of the minor child.
  2. Age: 6 months to < 21 years of age at time of study entry
  3. Histologically confirmed low-grade glioma in non-NF1 patients (no further biopsy is needed at study entry). For patients with NF1 and optic pathway glioma, no biopsy is required to confirm the radiological diagnosis of the low grade glioma.
  4. Relapse or refractory tumor after at least one first-line therapy, not taking into account surgery only.
  5. Evaluable Disease on morphologic MRI
  6. Karnofsky performance status score >=70% for patients >12 years of age, or Lansky score >=70% for patients <=12 years of age, including patients with motor paresis due to disease.
  7. Administration of stable dose of steroids for at least one week
  8. Life expectancy >= 3 months.
  9. Adequate organ function:

    • Adequate hematopoietic function: neutrophils ³1.0 x 109/L, platelets ³100 x 109/L; hemoglobin ³8 g/dL
    • Adequate renal function: serum creatinine < 1.5 x ULN for age In others cases where serum creatinine >1.5 ULN according to age, Glomerular filtration rate or creatinine clearance has to be >70 mL/min/1.73 m2 or >70% of the expected value
    • Adequate electrolytes levels: potassium, magnesium, phosphor, total calcium Lower Limit of Normal (LLN)
    • Adequate hepatic function: total bilirubin <=1.5 x ULN; AST and ALT <=2.5 x ULN.
    • Absence of peripheral neuropathy >= grade 2 (Common Toxicity Criteria Adverse Event, NCI CTCAE v4.0)
    • Adequate cardiac function:

    Shortening Fraction (SF) >= 28% (35% for children <3 years) and Left Ventricular Ejection Fraction (LVEF) >= 50% at baseline, as determined by echocardiography

    Absence of QTc prolongation (QTc > 450 msec on baseline ECG, using the QTcF formula) or other clinically significant ventricular or atrial arrhythmia

  10. Wash-out period of at least

    • 3 weeks in case of preliminary chemotherapy,
    • 6 weeks in case of nitrosourea-containing chemotherapy,
    • 2 weeks in the case of treatment with vincristine only
    • 6 weeks in case of radiation therapy
  11. Possibility of receiving the therapeutic schedule as indicated in the protocol
  12. Patients with reproductive potential must use effective contraception during their treatment and for up to 90 days after the last dose. Females with reproductive potential must have a negative pregnancy test <= 7 days before starting Nilotinib and/or Vinblastine.
  13. Patients already treated with one of the two drugs can be enrolled in the trial provided that rechallenging them with the same drug could be considered acceptable

Exclusion Criteria:

  1. Concomitant anti-tumor treatment
  2. Not recovered to <Grade 2 from the acute toxic effects of all prior chemotherapy, immunotherapy or radiotherapy
  3. Known intolerance or hypersensitivity to Vinblastine
  4. Existence of another severe systemic disease
  5. Uncontrolled infections not responsive to antibiotics, antiviral medicines, or antifungal medicines,
  6. Any concurrent illness which in the opinion of the investigator may interfere with the treatment and evaluation of the patient
  7. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of nilotinib.
  8. Simultaneous treatment with strong cytochromes P450 CYP3A4 inhibitors (e.g. antiepileptic drugs, see complete list in the Appendix 5).
  9. Simultaneous treatment with antiarrythmic drugs and other drugs known to prolong QT interval (cloroquine, halofantrine, clarithromycin, haloperidol, methadone, moxifloxacin, bepridil, cisapride and pimozide). A list of QT prolonging compounds can be found at (Appendix 6)
  10. Impaired cardiac function including any one of the following:

    • Clinically significant resting brachycardia (<50 beats per minute).
    • QTc > 450 msec on baseline ECG. If QTc >450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc.
    • Other clinically significant uncontrolled heart disease (e.g. unstable angina, congestive heart failure or uncontrolled hypertension).
    • History of or presence of clinically significant ventricular or atrial tachyarrhythmias (including congenital long QT syndrome or a known family history of congenital long QT syndrome)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01884922

Layout table for location contacts
Contact: Jacques GRILL, MD 0142116209 ext +33
Contact: Rudiger HASSELBERG 0142116250 ext +33

Layout table for location information
Medical University of Vienna Not yet recruiting
Vienna, Austria, A-1090
Contact: Amedeo AZIZI, MD   
Principal Investigator: Amedeo AZIZI, MD         
Rigshospitalet Not yet recruiting
Copenhagen, Denmark, DK - 2100
Contact: Karsten Nysom, MD-PhD    35 45 08 09 ext +45   
Principal Investigator: Karsten Nysom, MD-PhD         
Gustave Roussy Recruiting
Villejuif, Val de Marne, France, 94805
Contact: Jacques GRILL, MD    0142116209 ext +33   
Contact: Rudiger HASSELBERG    0142116250 ext +33   
Principal Investigator: Jacques GRILL, MD         
Koordinierungszentrum für Klinische Studien (KKS) der Charité Not yet recruiting
Berlin, Germany, 13353
Contact: Pablo HERNAIZ-DRIEVER, MD   
Principal Investigator: Pablo HERNAIZ-DRIEVER, MD         
University Hospital of Padua Not yet recruiting
Padua, Italy, 35128
Contact: Enrico OPOCHER, MD   
Principal Investigator: Enrico OPOCHER         
Erasmus MC/Sophia Children's Hospital Not yet recruiting
Rotterdam, Netherlands, 3015GJ
Contact: IM van der Sluis, MD-PhD    10 703 6691 ext +31   
Principal Investigator: IM van der Sluis, MD-PhD         
Fundació Sant Joan de Déu Not yet recruiting
Esplugues del Llobregat (Barcelona), Spain, 08950
Contact: Ofelia Cruz, MD    93 253 21 14 ext +34   
Principal Investigator: Ofelia Cruz, MD         
Swiss Pediatric Oncology Group Not yet recruiting
Bern, Switzerland, 3008
Contact: Nicolas Gerber, MD    44 266 31 17 ext +41   
Principal Investigator: Nicolas GERBER, MD         
United Kingdom
Cancer Research UK Clinical Trials Unit School of Cancer Sciences University of Birmingham Not yet recruiting
Edgbaston, Birmingham, United Kingdom, B15 2TT
Contact: Susan PICTON, MD   
Principal Investigator: Susan PICTON, MD         
Sponsors and Collaborators
Gustave Roussy, Cancer Campus, Grand Paris
Layout table for investigator information
Study Chair: Jacques GRILL, MD Gustave Roussy, Cancer Campus, Grand Paris
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Gustave Roussy, Cancer Campus, Grand Paris Identifier: NCT01884922    
Other Study ID Numbers: 2012-003005-10 Phase I
2012/1883 ( Other Identifier: CSET number )
022 ( Other Identifier: ITCC )
First Posted: June 24, 2013    Key Record Dates
Last Update Posted: January 26, 2017
Last Verified: January 2017
Keywords provided by Gustave Roussy, Cancer Campus, Grand Paris:
young adults
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action